Perovskite solar cells (PSCs) are among the most promising photovoltaic technologies owing to their exceptional optoelectronic properties1,2. However, the lower efficiency, poor stability and reproducibility issues of large-area PSCs compared with laboratory-scale PSCs are notable drawbacks that hinder their commercialization3. Here we report a synergistic dopant-additive combination strategy using methylammonium chloride (MACl) as the dopant and a Lewis-basic ionic-liquid additive, 1,3-bis(cyanomethyl)imidazolium chloride ([Bcmim]Cl). This strategy effectively inhibits the degradation of the perovskite precursor solution (PPS), suppresses the aggregation of MACl and results in phase-homogeneous and stable perovskite films with high crystallinity and fewer defects. This approach enabled the fabrication of perovskite solar modules (PSMs) that achieved a certified efficiency of 23.30% and ultimately stabilized at 22.97% over a 27.22-cm2 aperture area, marking the highest certified PSM performance. Furthermore, the PSMs showed long-term operational stability, maintaining 94.66% of the initial efficiency after 1,000 h under continuous one-sun illumination at room temperature. The interaction between [Bcmim]Cl and MACl was extensively studied to unravel the mechanism leading to an enhancement of device properties. Our approach holds substantial promise for bridging the benchtop-to-rooftop gap and advancing the production and commercialization of large-area perovskite photovoltaics.
Perovskite solar modules (PSMs) show outstanding power conversion efficiencies (PCEs), but long-term operational stability remains problematic. We show that incorporating N,N -dimethylmethyleneiminium chloride into the perovskite precursor solution formed dimethylammonium cation and that previously unobserved methyl tetrahydrotriazinium ([MTTZ] + ) cation effectively improved perovskite film. The in situ formation of [MTTZ] + cation increased the formation energy of iodine vacancies and enhanced the migration energy barrier of iodide and cesium ions, which suppressed nonradiative recombination, thermal decomposition, and phase segregation processes. The optimized PSMs achieved a record (certified) PCE of 23.2% with an aperture area of 27.2 cm 2 , with a stabilized PCE of 23.0%. The encapsulated PSM retained 87.0% of its initial PCE after ~1900 hours of maximum power point tracking at 85°C and 85% relative humidity under 1.0-sun illumination.
Ruthenium-based complexes have been suggested as promising anticancer drugs exhibiting reduced general toxicity compared to platinum-based drugs. In particular, Ru(η6-arene)(PTA)Cl2 (PTA = 1,3,5-triaza-7-phosphaadamantane), or RAPTA, complexes have demonstrated efficacy against breast cancer by suppressing metastasis, tumorigenicity, and inhibiting the replication of the human tumor suppressor gene BRCA1. However, RAPTA compounds have limited cytotoxicity, and therefore comparatively high doses are required. This study explores the activity of a series of RAPTA-like ruthenium(II) arene compounds against MCF-7 and MDA-MB-231 breast cancer cell lines and [Ru(η6-toluene)(PPh3)2Cl]+ was identified as a promising candidate. Notably, [Ru(η6-toluene)(PPh3)2Cl]Cl was found to be remarkably stable and highly cytotoxic, and selective to breast cancer cells. The minor groove of DNA was identified as a relevant target.
Single‐atom catalysts (SACs) present a promising subclass of classic heterogeneous catalysts by maximizing metal dispersion and enhancing efficiency. Although high‐density SACs (HD‐SACs) are reported, their synthesis is typically constrained to specific metal‐support combinations and high‐temperature annealing, limiting their translation to wider applications. Herein, a universal bottom‐up approach for the preparation of mono‐ and bimetallic HD‐SACs based on the polycondensation of 1,2,4,5‐benzenetetramine with a wide range of metal monomers containing 1,10‐phenanthroline‐5,6‐dione ligands is introduced. The synthesized materials are atomically dispersed and exhibit metal loadings up to 27.5 wt% with high structural stability. Their versatility as catalysts is explored in electrocatalytic and photocatalytic applications. The materials exhibit remarkable stability under operational conditions. Furthermore, this synthetic strategy is scaled up and automated, demonstrating the robustness and reproducibility and laying the groundwork for self‐optimizing data‐driven materials discovery.
Technologies for the transformation of atmospheric CO 2 to useful chemicals, such as formic acid (FA), are essential to combatting excessive fossil fuel use and will need to be implemented on large scale. However, hydrogenation of CO 2 to (base-free) FA is challenging for heterogeneous catalysts, due to the requirement for low temperatures enforced by the entropically unfavorable reaction of gases. By coupling CO 2 hydrogenation to esterification, methyl formate (MF) can be prepared as a promising alternative platform chemical. Herein, a robust, heterogeneous single-metal-site catalyst was prepared and shown to achieve methanol hydrocarboxylation rates superior to nanoparticle catalysts (up to 18.3 ± 0.6 mmol hour −1 ) while maintaining very high selectivity to MF (≥95%). Characterization reveals isolated, monodisperse Ru-nitrosyl complexes bound to three O-atoms of the zeolite framework, and the robust catalyst formed achieves a cumulative turnover number of more than 3500 over eight cycles. This work pushes the boundaries of supported single-site catalysts in CO 2 utilization.
Of the different modalities used to treat retinoblastoma, a chemothermotherapeutic regimen combining carboplatin and thermotherapy (also termed focal therapy), and the application of melphalan as a monotherapy, are particularly successful. Some studies indicate that melphalan shows potential when applied in combination with focal therapy, and yet is not applied in this combination. Here we describe a series of synthetically modified melphalan derivatives that display enhanced cytotoxicity relative to melphalan itself, with some displaying further enhancements in cytotoxicity when applied in combination with heat (used as a model for thermotherapy). The synthetic approach, which involves modifying melphalan with perfluorous chains of varying lengths via an ester linker, could lead to a more effective treatment option for retinoblastoma with reduced side-effects, which is a key limitation of melphalan.